{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "biomarker",
      "biopsy",
      "breast cancer premalignant lesion",
      "mammography"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "37096988",
  "DateCompleted": {
    "Year": "2023",
    "Month": "04",
    "Day": "26"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "05",
    "Day": "03"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2023",
        "Month": "04",
        "Day": "24"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.18632/oncotarget.28402"
    ],
    "Journal": {
      "ISSN": "1949-2553",
      "JournalIssue": {
        "Volume": "14",
        "PubDate": {
          "Year": "2023",
          "Month": "Apr",
          "Day": "24"
        }
      },
      "Title": "Oncotarget",
      "ISOAbbreviation": "Oncotarget"
    },
    "ArticleTitle": "Crossroads: the role of biomarkers in the management of lumps in the breast.",
    "Pagination": {
      "StartPage": "358",
      "EndPage": "362",
      "MedlinePgn": "358-362"
    },
    "Abstract": {
      "AbstractText": [
        "Premalignant lesions in the breast pose a difficult decision-making problem, whether to treat proactively and accept the side effects or to engage in watchful waiting and possibly encounter a later diagnosis of invasive cancer. A biomarker or set of biomarkers to inform on the individual progression risk would be beneficial to the patient and cost-effective for the healthcare system. The gene products of tumor progression may be expressed in early non-cancerous (\"premalignant\") lesions, where they are associated with a high probability for full transformation in breast cancers. One such molecule is the OPN splice variant-c. OPN-c is also present in a fraction of the premalignant lesions, where it reflects an elevated risk for progression to cancer within 5 years, regardless of the lesion's subtype. This marker has the properties needed to facilitate decisions to treat at the premalignant stage."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Cincinnati Academic Health Center, Cincinnati, OH 45267, USA."
          }
        ],
        "LastName": "Weber",
        "ForeName": "Georg F",
        "Initials": "GF"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Oncotarget",
    "NlmUniqueID": "101532965",
    "ISSNLinking": "1949-2553"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Biomarkers"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "pathology"
      ],
      "DescriptorName": "Breast"
    },
    {
      "QualifierName": [
        "pathology"
      ],
      "DescriptorName": "Breast Neoplasms"
    },
    {
      "QualifierName": [
        "pathology"
      ],
      "DescriptorName": "Precancerous Conditions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Biomarkers"
    }
  ]
}